2.87

0.00% 0.00

After Hours: 2.97 0.10 +3.48%

Organogenesis Holdings Inc (ORGO)

Overview News Price History Option Chain Financials Discussions Forecast

Organogenesis Holdings Inc stock is traded at $2.87, with a volume of 2.38M. It is up +0.00% in the last 24 hours and down -26.41% over the past month. Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Previous Close:

$2.87

Open:

$2.89

24h Volume:

2.38M

Relative Volume:

2.44

Market Cap:

$364.24M

Revenue:

$433.14M

Net Income/Loss:

$4.95M

P/E Ratio:

80.39

EPS:

0.0357

Net Cash Flow:

$6.55M

1W Performance:

-30.17%

1M Performance:

-26.41%

6M Performance:

-42.94%

1Y Performance:

-43.06%

1-Day Range:

$2.85

$2.995

1-Week Range:

$2.81

$4.13

52-Week Range:

$2.6101

$7.0771

Organogenesis Holdings Inc Stock (ORGO) Company Profile

Name

Organogenesis Holdings Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

781-575-0775

Address

85 DAN ROAD, CANTON, MA

Employee

869

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ORGO's Discussions on Twitter

Compare ORGO vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORGO Organogenesis Holdings Inc	2.87	364.24M	433.14M	4.95M	6.55M	0.0357
TAK Takeda Pharmaceutical Co Adr	18.22	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	125.96	53.16B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.47	47.25B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	32.91	37.59B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	490.21	21.85B	3.13B	1.27B	1.12B	26.39

Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Initiated	Lake Street	Buy
Feb-07-24	Initiated	Cantor Fitzgerald	Overweight
Jun-15-23	Initiated	Morgan Stanley	Equal-Weight
May-24-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Aug-10-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-10-20	Initiated	SVB Leerink	Outperform
Aug-26-19	Resumed	Credit Suisse	Outperform
May-02-19	Initiated	Credit Suisse	Outperform
Apr-17-19	Initiated	Oppenheimer	Outperform
Apr-11-19	Initiated	SunTrust	Buy

View All

Organogenesis Holdings Inc Stock (ORGO) Latest News

Mar 03, 2026

Organogenesis (ORGO) VP amends Form 4 for equity grant and tax withholding - Stock Titan

Mar 03, 2026

ORGO (Organogenesis) CEO amends Form 4 for stock grant and tax share disposal - Stock Titan

Mar 03, 2026

[Form 4/A] Organogenesis Holdings Inc. Amended Insider Trading Activity - Stock Titan

Mar 03, 2026

Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares - Stock Titan

Mar 03, 2026

Organogenesis (NASDAQ: ORGO) officer amends Form 4 for award and tax-withheld shares - Stock Titan

Mar 03, 2026

Feb 28, 2026

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 28, 2026

ORGO PE Ratio & Valuation, Is ORGO Overvalued - Intellectia AI

Feb 28, 2026

Wall Street Zen Downgrades Organogenesis (NASDAQ:ORGO) to Hold - MarketBeat

Feb 28, 2026

Feb 27, 2026